PAM
LCTX icon

Paradigm Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Paradigm Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-104,325
Closed -$320K – 820
2013
Q3 		$320K Buy
+104,325
New +$330K 0.05% 401

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Paradigm Asset Management's LCTX Position: Q4 2013 in Review

Paradigm Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2013, closing a stake of 104,325 shares — an estimated $320K sold.

Paradigm Asset Management first reported a position in LCTX in Q3 2013 and held it in 1 quarter. The position peaked at $320K in Q3 2013. 58 funds tracked by Wall St. Rank hold LCTX as of Q4 2013.

  • Paradigm Asset Management reported no remaining Lineage Cell Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Paradigm Asset Management sold 104,325 Lineage Cell Therapeutics shares in Q4 2013, an estimated $320K.
  • Paradigm Asset Management first reported a position in Lineage Cell Therapeutics in Q3 2013 and held it in 1 quarter.
  • Paradigm Asset Management's Lineage Cell Therapeutics position peaked at $320K in Q3 2013.
  • 58 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2013.

Based on Paradigm Asset Management's 13F filing for Q4 2013, filed 7 Feb 2014.